SAN FRANCISCO, CA--(Marketwired - February 23, 2015) - Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. That paradigm is changing, and CEL-SCI Corp. (NYSE MKT: CVM) is among the companies poised to bring immunotherapy into these disease spaces. In this interview with The Life Sciences Report, Geert Kersten, CEL-SCI’s CEO, describes how his company’s Multikine and L.E.A.P.S. platforms can be deployed, and how investors can turn an immunotherapeutic win into profit.
The Life Sciences Report: What makes CEL-SCI Corporation’s immunotherapy strategy stand out compared to more conventional chemotherapeutic approaches?
Geert Kersten: It’s really two things. The first relates to when to boost the immune system for greatest therapeutic effect. We believe the immune system should be boosted while it’s still healthy. More conventional approaches boost the immune system after it has been weakened by interventions such as surgery, radiation and chemotherapy. Boosting a healthy immune system is our key advantage.
The second relates to directing the immune system specifically to the cancer. Our technology makes the immune system specific inside the body, whereas other technologies provide that specificity outside the body, by either taking a piece of a patient’s tumor and making a vaccine from that or by using a monoclonal antibody that focuses on a subset of patients with a certain type of antigen...
Continue reading this interview with Geert Kersten: CEL-SCI Corp.'s Novel Immunotherapies Set Sights on Cancer, Autoimmune Disorders and Infectious Diseases.
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.
DISCLOSURE:
CEL-SCI Corp. paid The Life Sciences Report to conduct, produce and distribute the interview. Geert Kersten had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Geert Kersten and not of The Life Sciences Report or its officers.
Contact:
Brandon Fung
Tel: 707-981-8107
Help employers find you! Check out all the jobs and post your resume.
